<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02931344</url>
  </required_header>
  <id_info>
    <org_study_id>137.04</org_study_id>
    <nct_id>NCT02931344</nct_id>
  </id_info>
  <brief_title>Biomarkers in Obese Patients With Knee Osteoarthritis; Weight Loss</brief_title>
  <acronym>BIO-LOSEIT-I</acronym>
  <official_title>Biomarkers in Obese Patients With Knee Osteoarthritis Following a Significant Weight Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henrik Gudbergsen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Parker Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a substudy to a randomised trial investigating the effect of liraglutide on body
      weight and pain in overweight or obese patients with knee osteoarthritis (NCT02905864).

      This substudy aims to investigate any changes in biomarkers associated with the initial
      8-week weight loss intervention
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the parent trial, patients will be subjected to an 8-week diet intervention phase
      including a low-calorie diet and dietetic counselling, after which they will be randomised to
      receive either liraglutide 3 mg or liraglutide 3 mg placebo as an add-on to dietetic guidance
      on re-introducing regular foods and a focus on continued motivation to engage in a healthy
      lifestyle.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in collagen II degradation fragment α-C2M</measure>
    <time_frame>Week -8 to 0</time_frame>
    <description>Blood sampling</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in collagen II degradation fragment β-C2M</measure>
    <time_frame>Week -8 to 0</time_frame>
    <description>Blood sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in non-coding RNA type snoRNAs U38 and U48</measure>
    <time_frame>Week -8 to 0</time_frame>
    <description>Blood sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in miRNA-454</measure>
    <time_frame>Week -8 to 0</time_frame>
    <description>Blood sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in miRNA let-7e</measure>
    <time_frame>Week -8 to 0</time_frame>
    <description>Blood sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Nesfatin-1</measure>
    <time_frame>Week -8 to 0</time_frame>
    <description>Blood sampling</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Osteoarthrtis</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Intensive dietary intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Supervised dietary weight loss program lasting 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dietary Supplement: Dietary Supplement: Intensive dietary intervention</intervention_name>
    <description>Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.</description>
    <arm_group_label>Intensive dietary intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Same as parent trial (NCT02905864)

        Exclusion Criteria:

          -  Same as parent trial (NCT02905864)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Parker Institute</name>
      <address>
        <city>Frederiksberg</city>
        <state>Capital Region</state>
        <zip>2000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2016</study_first_submitted>
  <study_first_submitted_qc>October 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2016</study_first_posted>
  <last_update_submitted>April 19, 2018</last_update_submitted>
  <last_update_submitted_qc>April 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Parker Research Institute</investigator_affiliation>
    <investigator_full_name>Henrik Gudbergsen</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Osteoarthrtis</keyword>
  <keyword>Obesity</keyword>
  <keyword>Liraglutide 3 mg</keyword>
  <keyword>Liraglutide</keyword>
  <keyword>Biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

